Navidea Biopharma (NAVB) to Receive $1M in Lymphoseek-Related Milestone Payments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Navidea Achieves $1 Million in Lymphoseek® Commercial Milestones
September 22, 2016 6:59 AM EDT- Navidea earns a $500,000 payment from Cardinal Health, Inc. with the sale of the 100,000th Lymphoseek dose -
- Navidea to receive $500,000 payment from SpePharm AG, an affiliate of Norgine, B.V., for EMA approval of Lymphoseek single dose vial -
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) has announced it will receive payments totaling $1 million from two recently achieved Lymphoseek® commercial milestones under its distribution agreements with U.S. partner Cardinal Health, Inc. (Cardinal) and... More
